The Glucagon-Like Peptide-1 receptor (GLP-1R) agonists, which are already approved for the treatment of diabetes and obesity due to their weight loss-inducing effect [12,13,14,15], have recently been investigated to improve NAFLD in animals and humans, yielding promising results [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.